The results showed that levels of p-PERK (phosphorylated PERK) were reduced by treatment with siRNA (15 nM) or GSK2656157 (5 μM), however eIF2α was still activated by fisetin in hepatocellular carcinoma cells (Figure 3C–F). Here, EIF2A is linked to hepatocellular carcinoma.